Endoxifen - Intas Pharmaceuticals/Jina pharmaceuticals

Drug Profile

Endoxifen - Intas Pharmaceuticals/Jina pharmaceuticals

Alternative Names: 4-Hydroxy-N-desmethyltamoxifen; Z-endoxifen

Latest Information Update: 22 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intas Pharmaceuticals; Jina Pharmaceuticals
  • Developer Intas Pharmaceuticals; Jina Pharmaceuticals; National Cancer Institute (USA)
  • Class Antineoplastics; Methylamines; Phenyl ethers; Stilbenes
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bipolar disorders
  • Phase II Breast cancer
  • Phase I Fibroma; Gynaecological cancer

Most Recent Events

  • 01 Jun 2018 Phase-I clinical trials in Fibroma in USA (PO)
  • 01 Jun 2018 Phase-I clinical trials in Gynaecological cancer in USA (PO)
  • 01 Jun 2018 Efficacy, adverse events, pharmacodynamics and pharmacokinetic data from a phase I study in Advanced solid tumours study (Late-stage) presented at 54th Annual Meeting of Clinical Oncology (ASCO – 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top